In vitro activity of gemifloxacin compared with other antimicrobial agents against recent clinical isolates of streptococci

Journal of Antimicrobial Chemotherapy

Volumn 45, Issue 4 SUPPL. S1, 2000, Pages 51-53

  Ieven, Margareta ^a   Goossens, Wendy ^a   De Wit, Stefan ^a   Goossens, Herman ^a  

^a ANTWERP UNIVERSITY HOSPITAL   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

AMPICILLIN; AZITHROMYCIN; CIPROFLOXACIN; CLARITHROMYCIN; GEMIFLOXACIN; GREPAFLOXACIN; LEVOFLOXACIN; OFLOXACIN; PENICILLIN G; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TROVAFLOXACIN;

ALPHA HEMOLYTIC STREPTOCOCCUS; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC SENSITIVITY; ARTICLE; DRUG POTENCY; HUMAN; MINIMUM INHIBITORY CONCENTRATION; STREPTOCOCCUS AGALACTIAE; STREPTOCOCCUS INFECTION; STREPTOCOCCUS PYOGENES;

ANTI-INFECTIVE AGENTS; FLUOROQUINOLONES; HUMANS; MICROBIAL SENSITIVITY TESTS; NAPHTHYRIDINES; STREPTOCOCCUS; STREPTOCOCCUS AGALACTIAE; STREPTOCOCCUS PYOGENES;

EID: 0034128548     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Oppenheim, B. A. (1998). The changing pattern of infection in neutropenic patients. Journal of Antimicrobial Chemotherapy 41, Suppl. D, 7-11.
2. Cormican, M. G. & Jones, R. N. (1996). Emerging resistance to antimicrobial agents in Gram-positive bacteria. Enterococci, staphylococci and non-pneumococcal streptococci. Drugs 51, Suppl. 1, 6-12.
3. Pfaller, M. A., Jones R. N., Doem, G. V., Sader, H. S., Kugler, K. C. & Beach, M. L. (1999). Survey of blood stream infections attributable to gram-positive cocci: frequency of occurrence and antimicrobial susceptibility of isolates collected in 1997 in the United States, Canada and Latin America from the Sentry antimicrobial Surveillance Program. Diagnostic Microbiology and Infectious Disease 33, 283-97.
4. Johnson, D. M., Jones, R. N. & Erwin, M. E. (1999). Anti-streptococcal activity of SB-285805 (LB20304), a novel fluoronaphthyridone, compared with five other compounds including quality control guidelines. Diagnostic Microbiology and Infectious Disease 33, 85-91.
5. Kim, Y. F., Choi, H., Kim, S. H., Chang, J. H., Nam, N. H., Kim, Y. Z. et al. (1995) Synthesis and antimicrobial activities of LB 20304, a new fluoronaphthyridone antibiotic containing novel functionalized pyrrolidine. In Program and Abstracts of the Thirty-Fifth Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, Abstract F204, p. 148. American Society for Microbiology, Washington, DC.
6. Oh, J. I., Paek, K. S., Ahn, M. J., Kim, M. Y., Hong, C. Y., Kim, I. C. et al. (1996). In vitro and in vivo evaluations of LB 20304, a new fluoronaphthyridone. Antimicrobial Agents and Chemotherapy 40, 1564-8.
7. Cormican, M. G. & Jones, R. N. (1997). Antimicrobial activity and spectrum of LB 20304, a novel fluoronaphthyridone. Antimicrobial Agents and Chemotherapy 41, 204-11.
8. Hohl, A. F., Frei, R., Punter, V., von Graevenitz, A., Knapp, C., Washington, J. A. et al. (1998). International multi-center investigation of LB 20304, a new fluoronaphthyridone. Clinical Microbiology and Infection 4, 280-4.
9. Marco, F., Barrett, M. S. & Jones, R. N. (1997). Antimicrobial activity of LB 20304, a fluoronaphthyridone, tested against anaerobic bacteria. Journal of Antimicrobial Chemotherapy 40, 605-7.
10. National Committee for Clinical Laboratory Standards. (1999). Performance Standards for Antimicrobial Susceptibility Testing: Ninth Informational Supplement, M100-S9. NCCLS, Wayne, PA.
11. Pfaller, M. A. & Jones, R. N. (1997). Comparative antistreptococcal activity of two newer fluoroquinolones, levofloxacin and sparfloxacin. Diagnostic Microbiology and Infectious Disease 29, 199-201.
12. Carratala, J., Alcaide, F., Fernandez-Sevilla, A., Corbella, X., Linares, J. & Gudiol, F. (1995). Bacteremia due to viridans streptococci that are highly resistant to penicillin: increase among neutropenic patients with cancer. Clinical Infectious Diseases 20, 1169-73.
13. Doern, G. V., Ferraro, M. J., Bruggemann, A. B. & Ruoff, K. L. (1996). Emergence of high rates of resistance among viridans group streptococci in the United States. Antimicrobial Agents and Chemotherapy 40, 891-4.
14. Tuohy, M. & Washington, J. A. (1997). Antimicrobial susceptibility of viridans group streptococci. Diagnostic Microbiology and Infectious Disease 29, 277-80.
15. Alcaide, F., Linares, J., Pallares, R., Carratala, J., Benitez, M. A., Gudiol, F. et al. (1995). In vitro activity of 22 β-lactam antibiotics against penicillin-resistant and penicillin-susceptible viridans group streptococci isolated from blood. Antimicrobial Agents and Chemotherapy 39, 2243-7.